ReviewDiagnostics (Basel, Switzerland)2022
Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Predictors of postoperative morbidity and delayed initiation of adjuvant chemotherapy after cytoreductive surgery in advanced-stage epithelial ovarian cancer.World journal of surgical oncology · 2026Article
- Liposomal Vitamin C as a Modulator of the Efficacy of Ceralasertib Therapy in Ovarian Cancer.International journal of molecular sciences · 2026Article
- Schlafen 11 (SLFN11) And Tumor-Infiltrating Lymphocytes (TILs): Dual Predictive Biomarkers In Ovarian Serous Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Changes in Epithelial Ovarian Cancer Recurrence and Survival According to Treatment Paradigm Shifts.The journal of obstetrics and gynaecology research · 2026Article
- Eastern Cooperative Oncology Group classification and its application in surgical treatment planning of epithelial ovarian cancer.Frontiers in oncology · 2026Article
- Integrative Genomic and Functional Analysis Reveals NF1 Loss as a Modifier of DNA Damage and Replication Stress Responses in Ovarian Cancer.Human mutation · 2026Article
- Port-site metastases after diagnostic laparoscopy in advanced ovarian cancer: a case report and a systematic review of the literature.Frontiers in surgery · 2026Review
- Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Patients with Advanced Primary Epithelial Ovarian Cancer in Low Resources Setting: A Randomized Clinical Trial.Journal of obstetrics and gynaecology of India · 2025Article
- Yolk sac ovarian cancer with mesenteric metastases.BMJ case reports · 2025Article
- Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation inInternational journal of molecular sciences · 2025Article
- Comment on "Oncovascular surgery".Revista da Associacao Medica Brasileira (1992) · 2025Article
- Clinical effects of debulking surgery combined with neoadjuvant chemotherapy in treating ovarian cancer and its influence on tumor markers and immune function.Pakistan journal of medical sciences · 2024Article
- The predictive role of PD-L1 expression and CD8 + TIL levels in determining the neoadjuvant chemotherapy response in advanced ovarian cancer.Journal of ovarian research · 2024Article
- Secondary cytoreduction in recurrent ovarian cancer- experience from a tertiary care centre in India.Gynecologic oncology reports · 2024Article
- Review
- Determination of quality of life-related health utilities for surgical complications in ovarian cancer.Gynecologic oncology · 2024Article
- Splenectomy as Part of Maximal-Effort Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.Cancers · 2024Article
- Neglected Anatomical Areas in Ovarian Cancer: Significance for Optimal Debulking Surgery.Cancers · 2024Review
- Article
- LncRNA HOTAIR down-expression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing TGF-β1 and ZEB1.Discover oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary debulking surgery (PDS) has remained the only treatment of ovarian cancer with survival advantage since its development in the 1970s. However, survival advantage is only observed in patients who are optimally resected. Neoadjuvant chemotherapy (NACT) has emerged as an alternative for patients in whom optimal resection is unlikely and/or patients with comorbidities at high risk for perioperative complications. The purpose of this review is to summarize the evidence to date for PDS and NACT in the treatment of stage III/IV ovarian carcinoma. We systematically searched the PubMed database for relevant articles. Prior to 2010, NACT was reserved for non-surgical candidates. After publication of EORTC 55971, the first randomized trial demonstrating non-inferiority of NACT followed by interval debulking surgery, NACT was considered in a wider breadth of patients. Since EORTC 55971, 3 randomized trials-CHORUS, JCOG0602, and SCORPION-have studied NACT versus PDS. While CHORUS supported EORTC 55971, JCOG0602 failed to demonstrate non-inferiority and SCORPION failed to demonstrate superiority of NACT. Despite conflicting data, a subset of patients would benefit from NACT while preserving survival including poor surgical candidates and inoperable disease. Further randomized trials are needed to assess the role of NACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.